Amundi Has $439.04 Million Stake in Zoetis Inc. $ZTS

Amundi cut its position in Zoetis Inc. (NYSE:ZTS) by 23.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,748,011 shares of the company’s stock after selling 847,617 shares during the quarter. Amundi owned 0.62% of Zoetis worth $439,038,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Nova Wealth Management Inc. bought a new stake in shares of Zoetis in the first quarter worth $25,000. 1248 Management LLC acquired a new position in Zoetis during the 1st quarter worth about $27,000. Saudi Central Bank bought a new stake in shares of Zoetis in the 1st quarter valued at about $29,000. REAP Financial Group LLC increased its stake in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares during the period. Finally, NewSquare Capital LLC increased its stake in shares of Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after buying an additional 85 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently commented on ZTS. Piper Sandler upped their target price on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Morgan Stanley dropped their price target on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday, November 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. UBS Group lowered their target price on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. Finally, KeyCorp started coverage on Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating for the company. Six equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $178.89.

Zoetis Stock Down 1.4%

ZTS stock opened at $118.69 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $181.85. The stock’s 50 day simple moving average is $133.77 and its 200 day simple moving average is $147.78. The company has a market cap of $52.31 billion, a P/E ratio of 19.98, a price-to-earnings-growth ratio of 2.50 and a beta of 0.97.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same period in the prior year, the firm earned $1.58 earnings per share. Zoetis’s revenue for the quarter was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st were issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date was Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.